Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Hexagon Bio discovers and develops new cancer therapies using microbial natural products, genomic data, and artificial intelligence.
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
Apella Technology is an AI startup that brings modern engineering to improve surgery.
Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.
Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.
A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.
Deepcell is a life science company specializing in AI-powered single-cell classification and isolation for basic and translational research.
Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Xcell Biosciences is a next-generation development and manufacturing platform for enhanced cell therapy performance.
Arzeda is a protein design company that creates and manufactures proteins and enzymes for pharmaceuticals and industrial chemicals.
TMRW Life Sciences provides an integrated platform for automated, software-guided cryospecimen management.
Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.
Genomic Life offers genomic products.
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Flexible tools for single cell analysis
Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.
Octave is a precision care company that provides diagnostic tools and care solutions for neurodegenerative diseases.
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.
Casdin Capital has invested in 95 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Casdin Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 24 different industry categories.
Among tracked funding rounds, Revolution Medicines received $1.5B in a Post-IPO Equity round. Casdin Capital's total known invested capital is $6.8B.
Casdin Capital's average investment size is $71.7M across its portfolio of 95 companies.
Recent Casdin Capital portfolio additions include Hexagon Bio, 4D Molecular Therapeutics, Revolution Medicines, Foghorn Therapeutics, Apella Technology. These companies were founded in 2020 or later.